Studies on Pol III-Associated Leukodystrophy
Studies on Pol III-Associated Leukodystrophy
批准号:
10076558
负责人:
Robyn Moir
金额:
$20.88万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-01 至 2021-02-28
关键词:
6 year oldAffectAgeAnimalsBehaviorBehavioralBiogenesisBiological ModelsBrainCatalytic DomainCell Differentiation processCell physiologyCellular StressCerebrumCharacteristicsChemicalsChildhoodChronicClinicalClinical/RadiologicCognitive deficitsDNA Polymerase IDNA Polymerase IIIDNA-Directed RNA PolymeraseDefectDevelopmental Delay DisordersDiagnosisDietDiseaseDisease ProgressionElectron MicroscopyElectron Transport Complex IIIEndocrineEnzymesEukaryotaExhibitsGenesGeneticGenetic ModelsGenetic SuppressionGenetic TranscriptionGoalsHumanHypodontiaImmunohistochemistryImpairmentIntellectual functioning disabilityKnock-in MouseKnock-outKnockout MiceLaboratoriesLinkMagnetic Resonance ImagingMammalsMeasuresMissense MutationMolecularMotorMusMutant Strains MiceMutationMyelinMyopiaNerve DegenerationNeurodegenerative DisordersNeuronsNutritionalObesityOnset of illnessPathogenesisPatientsPhenotypePolymerasePopulationProductionProliferatingProtein BiosynthesisProteinsRadiology SpecialtyRepressionResearchResistanceSaccharomycetalesSensorimotor functionsSeveritiesSeverity of illnessTestingTherapeuticThinnessTissuesTransfer RNATranslationsUntranslated RNAWorkbasecognitive functioncognitive regressiondisease phenotypeexperimental studyleukodystrophymouse modelnegative affectneuropathologypreventresponseribosome profilingtargeted treatmenttherapeutic evaluationwhite matter
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Pol III-associated leukodystrophy is an autosomal recessive neurodegenerative disease linked to mutations
in subunits of RNA polymerase III (Pol III). The clinical and radiologic spectrum of the disorder has only
recently been defined. Pol III-associated leukodystrophy is characterized by hypomyelination of cerebral white
matter and presents as a progressive decline in motor function, developmental delay and intellectual disability.
Disease onset typically occurs during childhood but the age range at diagnosis is broad, reflecting the variable
severity and slow progression of the disease. Other clinical characteristics include myopia, hypodontia and
endocrine abnormalities but these features are not always present. The mechanism of pathogenesis is
unknown and no therapeutic options are available. Further progress in understanding this disease is limited by
the lack of model systems. Thus, the goal of this research is to develop a mouse model of Pol III-associated
leukodystrophy. We have created a knock-in mouse expressing clinically-defined Pol III-associated
leukodystrophy mutations. We will characterize the behavioral, radiologic and neuropathologic phenotypes of
these mice. Phenotypic changes will be correlated with the impact of the mutation on Pol III transcription, tRNA
biogenesis and protein synthesis. In addition, we will test a model for genetic suppression of Pol III-associated
leukodystrophy phenotypes. These studies will significantly enhance understanding of the pathogenesis of Pol
III-associated leukodystrophy and will provide a model system for testing therapeutic approaches targeting the
disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A whole body model of Pol III-related leukodystrophy
-
批准号:10287751
-
项目类别:
-
资助金额:$46.2万
-
财政年份:2021
-
负责人:Robyn Moir
-
依托单位:
海外基金